CINECA IRIS Institutional Research Information System

VITALE, Candida
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.704
EU - Europa 3.548
AS - Asia 2.125
AF - Africa 89
SA - Sud America 69
OC - Oceania 23
Continente sconosciuto - Info sul continente non disponibili 22
Totale 11.580
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.639
CN - Cina 1.034
IT - Italia 839
SG - Singapore 629
IE - Irlanda 494
DE - Germania 461
SE - Svezia 393
UA - Ucraina 266
AT - Austria 227
FI - Finlandia 223
FR - Francia 189
IN - India 90
VN - Vietnam 89
GB - Regno Unito 81
KR - Corea 80
PL - Polonia 68
NL - Olanda 59
BR - Brasile 57
CA - Canada 56
SN - Senegal 54
DK - Danimarca 53
HK - Hong Kong 51
ID - Indonesia 43
BY - Bielorussia 34
JP - Giappone 30
GR - Grecia 28
RU - Federazione Russa 27
BE - Belgio 25
ES - Italia 23
CH - Svizzera 21
EU - Europa 21
AU - Australia 17
TW - Taiwan 14
UZ - Uzbekistan 12
IR - Iran 9
RO - Romania 9
LT - Lituania 8
MX - Messico 8
TR - Turchia 7
ZA - Sudafrica 7
EG - Egitto 6
IL - Israele 6
NZ - Nuova Zelanda 6
AR - Argentina 5
IQ - Iraq 5
MA - Marocco 5
PT - Portogallo 5
SA - Arabia Saudita 5
TH - Thailandia 5
AM - Armenia 4
NG - Nigeria 4
PK - Pakistan 4
CO - Colombia 3
MY - Malesia 3
RS - Serbia 3
BD - Bangladesh 2
CI - Costa d'Avorio 2
CZ - Repubblica Ceca 2
DZ - Algeria 2
ET - Etiopia 2
HU - Ungheria 2
LU - Lussemburgo 2
MU - Mauritius 2
NO - Norvegia 2
PE - Perù 2
PH - Filippine 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AL - Albania 1
AO - Angola 1
BG - Bulgaria 1
BW - Botswana 1
EC - Ecuador 1
IM - Isola di Man 1
KE - Kenya 1
MK - Macedonia 1
MM - Myanmar 1
PA - Panama 1
TG - Togo 1
TN - Tunisia 1
UY - Uruguay 1
Totale 11.580
Salva come PNG Salva come JPEG
Città #
Chandler 850
Beijing 583
Dublin 493
Santa Clara 445
Singapore 410
Ann Arbor 269
Ashburn 258
Fairfield 221
Vienna 217
Houston 214
Jacksonville 199
Medford 180
Nyköping 171
Torino 171
Wilmington 168
Dearborn 167
Princeton 144
Columbus 142
Woodbridge 116
Munich 107
Helsinki 103
San Mateo 101
Turin 98
Seattle 92
Villeurbanne 80
Redwood City 72
Cambridge 69
Fremont 61
Dong Ket 58
Warsaw 53
New York 47
Florence 42
Jakarta 42
Guangzhou 39
Nanjing 35
Washington 32
Chengdu 30
Toronto 30
Hangzhou 29
Hefei 29
Milan 29
Pisa 28
Rome 28
Hong Kong 24
Los Angeles 24
Shanghai 24
Brussels 23
Nuremberg 23
Boston 22
Norwalk 22
San Diego 22
Chennai 20
Seoul 20
Falkenstein 19
Central District 17
Boardman 16
Düsseldorf 16
San Jose 16
Ottawa 15
Wuhan 14
Nürnberg 13
Silver Spring 13
Kunming 12
São Paulo 12
Taipei 12
Zhengzhou 12
Bologna 11
Chieri 11
Hebei 11
Upper Marlboro 11
Duncan 9
Falls Church 9
Frankfurt am Main 9
Linden 9
London 9
Nanchang 9
Rotterdam 9
Guiyang 8
Hyderabad 8
Jyväskylä 8
Oerlikon 8
Paris 8
Piemonte 8
Provo 8
Pune 8
Shenyang 8
Xian 8
Changsha 7
Chicago 7
Codogno 7
Jinan 7
Mountain View 7
Philadelphia 7
Phoenix 7
Tokyo 7
Amsterdam 6
Dallas 6
Liverpool 6
Madrid 6
Monza 6
Totale 7.436
Salva come PNG Salva come JPEG
Nome #
Adoptive immunotherapy with CAR modified T cells in cancer: current landscape and future perspectives 302
REGULATION OF HIF-1 alpha IN TP53 DISRUPTED CHRONIC LYMPHOCYTIC LEUKEMIA CELLS AND ITS POTENTIAL ROLE AS A THERAPEUTIC TARGET 296
IGHV unmutated CLL B cells are more prone to spontaneous apoptosis and subject to environmental prosurvival signals than mutated CLL B cells 291
Anergic bone marrow Vγ9Vδ2 T cells as early and long-lasting markers of PD-1-targetable microenvironment-induced immune suppression in human myeloma 207
The Defective Proliferation of Vgamma9Vdelta2 T Cells to Zoledronic Acid In Chronic Lymphocytic Leukemia (CLL) Is a Powerful Time to First Treatment (TFT) Predictor Associated with the IGHV Mutational Status. 205
Centralized Biobanking Supports Hematology Clinical Trials: the new challenge of the University of Torino 199
Regulation of HIF-1α in TP53 disrupted chronic lymphocytic leukemia cells and its potential role as a therapeutic target 185
Richter Syndrome in Chronic Lymphocytic Leukemia 172
Simvastatin and downstream inhibitors circumvent constitutive and stromal cell-induced resistance to doxorubicin in IGHV unmutated CLL cells 165
HIF-1α is overexpressed in leukemic cells from TP53-disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemia 157
Magic pills: new oral drugs to treat chronic lymphocytic leukemia 151
Humoral immune responses toward tumor-derived antigens in previously untreated patients with chronic lymphocytic leukemia 146
Final Report of Bendamustine and Alemtuzumab (BEN CAM) Combination in Relapsed and Refractory Chronic Lymphocytic Leukemia 142
The Advent of CAR T-Cell Therapy for Lymphoproliferative Neoplasms: Integrating Research Into Clinical Practice 140
The Mevalonate Pathway and Downstream Signal Transducers As Therapeutic Targets to Overcome Multidrug Resistance in Chronic Lymphocytic Leukemia (CLL) 136
CAR T-Cell Therapy for B-Cell non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia: Clinical Trials and Real-World Experiences 135
Identification of Novel Tumor-Associated Antigens in Chronic Lymphocytic Leukemia (CLL) by Serological Proteome Analysis (SERPA) 134
IDENTIFICATION BY SEROLOGICAL PROTEOME ANALYSIS (SERPA) OF TUMOR-ASSOCIATED ANTIGENS ELICITING ANTIBODY RESPONSES IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) 122
Autoimmune complications in chronic lymphocytic leukemia in the era of targeted drugs 121
Selinexor in Combination with Chemotherapy or Idelalisib Elicits a Synergistic Cytotoxic Effect in Primary CLL Cells, Also Overcoming Intrinsic and Stromal Cells-Mediated Fludarabine Resistance 117
The Mevalonate Pathway As a Metabolic Target to Circumvent Multidrug-Resistance in Chronic Lymphocytic Leukemia Cells 116
Pre-existing and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugs 116
The tryptophan metabolism in the immune dysregulation of multiple myeloma 113
Regulation of HIF-1α in TP53 Disrupted Chronic Lymphocytic Leukemia Cells and Its Potential Role as a Therapeutic Target 113
THE LOCAL MICROENVIRONMENT PLAYS A DIFFERENT ROLE IN THE SURVIVAL OF TUMOR CELLS IN CHRONIC LYMPHOCYTIC LEUKEMIA WITH MUTATED AND UNMUTATED IMMUNOGLOBULIN (IG) VH GENES 112
Identification and functional characterization of tumor specific antibody responses in chronic lymphocytic leukemia 111
Role of PD-1/PD-L1 axis in the immune paresis of bone marrow Vγ9Vδ2 T cells in multiple myeloma 110
Idelalisib nei pazienti con leucemia linfatica cronica e linfoma follicolare: esperienza monocentrica real life 110
IDENTIFICATION AND FUNCTIONAL CHARACTERIZATION OF ANTIBODY IMMUNE RESPONSES ELICITED BY SELF ANTIGENS IN CHRONIC LYMPHOCYTIC LEUKEMIA 108
Accelerated activity of the mevalonate pathway supports the immune escape and multidrug-resistance phenotype of IGHV unmutated chronic lymphocytic leukemia cells 107
IMPACT OF THE MEVALONATE PATHWAY AND HIF/PGP AXIS IN MODULATING MULTIDRUG-RESISTANCE IN UNMUTATED CLL CELLS 107
Autoimmune cytopenias in patients with chronic lymphocytic leukemia treated with ibrutinib 107
Targeting the mevalonate pathway and downstream signaling pathways as a strategy to circumvent multidrug-resistance in CLL cells 106
Serological Proteome Analysis (SERPA) as a tool for the identification of novel tumor antigens in chronic lymphocytic leukemia (CLL) 106
COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study 104
The metabolism of mevalonate as a signaling pathway influencing tumor-host interactions and disease progression in chronic lymphocytic leukemia (CLL) 102
Real life use of bendamustine in elderly patients with lymphoid neoplasia 102
t(9;22) as secondary alteration in core-binding factor de novo acute myeloid leukemia 100
SELINEXOR (KPT-330) IN COMBINATION WITH CHEMOTHERAPY OR IDELALISIB ELICITS A SYNERGISTIC CYTOTOXIC EFFECT IN PRIMARY CLL CELLS, ALSO OVERCOMING INTRINSIC AND STROMAL CELLS-MEDIATED FLUDARABINE RESISTANCE 100
IGHV Unmutated Chronic Lymphocytic Leukemia (CLL) B Cells Are More Susceptible to Spontaneous Apoptosis Than Mutated CLL B Cells and Are Subject to the Anti-Apoptotic Effect of Environmental Signals 97
Differential Effects of Microenvironmental Elements On Tumor Cells Survival in Chronic Lymphocytic Leukemia Patient Subsets with Good or Poor Prognosis 97
SEROLOGICAL PROTEOME ANALYSIS (SERPA) FOR THE IDENTIFICATION OF TUMOR-ASSOCIATED ANTIGENS ELICITING ANTIBODY-RESPONSES IN CHRONIC LYMPHOCYTIC LEUKEMIA 97
Prognostic relevance of oxidative stress measurement in chronic lymphocytic leukaemia 96
Identification by serological proteome analysis (SERPA) of tumor-associated antigens eliciting antibody-responses in chronic lymphocytic leukemia 96
Identification by serological proteome analysis (SERPA) of novel tumor associated antigens in chronic lymphocytic leukemia (CLL) 93
Serological proteome analysis (SERPA) as a tool for the identification of tumor antigens capable of eliciting immune responses in chronic lymphocytic leukemia (CLL) 93
Ibrutinib Treatment Mitigates Phenotypic Alterations of Non-Neoplastic Immune Cell Compartments in Chronic Lymphocytic Leukemia 93
Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib–rituximab 93
Comprehensive assessment of the TCRBV repertoire in small T-cell samples by means of an improved and convenient multiplex PCR method 92
Dysfunctional Vγ9Vδ2 T cells are negative prognosticators and markers of dysregulated mevalonate pathway activity in chronic lymphocytic leukemia cells. 92
CD200 INCLUDED IN A 4-MARKER MODIFIED MATUTES SCORE PROVIDES OPTIMAL SENSITIVITYAND SPECIFICITY FOR THE DIAGNOSIS OF CHRONIC LYMPHOCYTIC LEUKEMIA 91
BENDAMUSTINE AND ALEMTUZUMAB (BEN CAM) COMBINATION IN RELAPSED AND REFRACTORY CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL): PHASE I SAFETY PROFILE RESULTS OF THE ITALIAN TRIAL 89
HIF-1 alpha Upregulation in TP53 Disrupted Chronic Lymphocytic Leukemia Cells and Its Potential Role As a Therapeutic Target 88
PHENOTYPIC AND FUNCTIONAL FEATURES OF VGAMMA9/VDELTA2 T CELLS CORRELATE WITH THE MUTATIONAL STATUS OF THE TUMOR IMMUNOGLOBULINE AND WITH DISEASE AGGRESSIVENESS IN CHRONIC LYMPHOCYTIC LEUKEMIA 87
THE SURVIVAL OF TUMOR CELLS IN IGVH UNMUTATED CHRONIC LYMPHOCYTIC LEUKEMIA IS HIGHLY DEPENDENT ON EXOGENOUS SIGNALS DELIVERED BY THE TUMOR MICROENVIRONMENT 85
The CXCR4 downstream signaling pathways in chronic lymphocytic leukemia: a target to reverse microenvironment protection 85
Role of ward pharmacist in management of systemic antifungal drugs in hematology department of San Giovanni Battista Hospital, Turin, Italy. 84
Chronic lymphocytic leukemia therapy: new targeted therapies on the way 84
TARGETING THE CXCR4 DOWNSTREAM SIGNALLING PATHWAYS TO REVERSE MICROENVIRONMENT PROTECTION IN CHRONIC LYMPHOCYTIC LEUKEMIA CELLS 84
Bendamustine and alemtuzumab (BEN CAM) combination in relapsed and refractory chronic lymphocytic leukaemia (CLL): interim report of the italian trial 83
LDH as Predictive Parameter in Treatment-Naïve Patients Affected by Chronic Lymphocytic Leukemia with Trisomy 12 83
Targeting hif-1α regulatory pathways as a strategy to hamper tumor-microenvironment interactions in cll 82
The Hypoxia-Inducible Factor-1 alpha Is Constitutively Upregulated in TP53 Disrupted CLL Cells: A Potential Target to Overcome Fludarabine Resistance 81
The Mevalonate Metabolic Pathway and the CXCL12/CXCR4 Axis Reciprocally Interact and Are Implicated in Fludarabine Resistance of Chronic Lymphocytic Leukemia Cells 81
Outcome of Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) and/or 17p Deletion/TP53 Mutations Treated with Ibrutinib According to a Named Patient Program (NPP) in Italy: Preliminary Analysis of a Real Life Retrospective Study 81
Mutual interactions between tumor cells, the immune system and the microenvironment in chronic lymphocytic leukemia: biological insights and potential therapeutic implications 81
Regulation of HIF-1α in TP53 disrupted chronic lymphocytic leukemia cells and its potential role as a therapeutic target 80
Abstract 2072: Selinexor in combination with chemotherapy or idelalisib elicits a synergistic cytotoxic effect in primary CLL cells 80
Pre-Existing and Treatment-Emergent Autoimmune Cytopenias in Patients with Chronic Lymphocytic Leukemia Treated with Targeted Drugs 79
Evaluation of the cytotoxic effect of selinexor in combination with chemotherapy or idelalisib towards primary CLL cells 79
COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus 79
The enzymatic activities of CD38 enhance CLL growth and trafficking: implications for therapeutic targeting. 79
Ofatumumab and lenalidomide for patients with relapsed or refractory chronic lymphocytic leukemia: Correlation between responses and immune characteristics 78
B-cell Acute Lymphoblastic Leukemia in Patients with Chronic Lymphocytic Leukemia Treated with Lenalidomide 78
The association of dexamethasone + simvastatin to overcome environment-mediated chemoresistance of chronic lymphocytic leukemia (CLL) cells 77
SEROLOGICAL PROTEOME ANALYSIS (SERPA) FOR THEIDENTIFICATION OF NOVEL TUMOR-ASSOCIATED ANTIGENS INCHRONIC LYMPHOCYTIC LEUKEMIA 76
Cd200 baseline serum levels predict prognosis of chronic lymphocytic leukemia 76
Bendamustine and Alemtuzumab combination in relapsed and refractory chronic lymphocytic leukemia: interim report of the italian trial 75
The role of clinical team pharmacist of San Giovanni Battista Hospital in a retrospective study invasive fungine infections: management and appropiateness. 75
Modulation of Phenotypic and Functional Features of Immune Cells in Chronic Lymphocytic Leukemia Patients Treated with Ibrutinib 75
IGHV UNMUTATED CLL B CELLS ARE MORE PRONE TO SPONTANEOUS APOPTOSIS AND DEPEND FROM THE ANTI-APOPTOTIC EFFECT OF ENVIRONMENTAL SIGNALS 74
TARGETING HIF-1 AND ITS REGULATORY PATHWAYS AS A STRATEGY TO HAMPER TUMOR-MICROENVIRONMENT INTERACTIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA 74
TARGETING HIF-1A AND ITS REGULATORY PATHWAYS AS A STRATEGY TO HAMPER LEUKEMIA-MICROENVIRONMENT INTERACTIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA 73
REGULATION OF HIF-1 IN TP53 DISRUPTED CLL CELLS AND ITS INHIBITION AS A STRATEGY TO OVERCOME FLUDARABINE RESISTANCE 72
CD200 included in a 4-marker modified Matutes score provides optimal sensitivity and specificity for the diagnosis of chronic lymphocytic leukaemia 70
Lenalidomide can be safely combined with chlorambucil and rituximab in older patients with chronic lymphocytic leukemia 69
Elevated lactate dehydrogenase has prognostic relevance in treatment-naïve patients affected by chronic lymphocytic leukemia with trisomy 12 67
LDH Levels Predict Progression-Free Survival in Treatment-NaIVe Patients with Trisomy 12 Chronic Lymphocytic Leukemia 66
Immune dysfunctions and immune-based therapeutic interventions in chronic lymphocytic leukemia 66
Ibrutinib Treatment Mitigates Phenotypic Alterations of Non-Neoplastic Immune Cell Compartments in Chronic Lymphocytic Leukemia 65
Impact of immune parameters and immune dysfunctions on the prognosis of patients with chronic lymphocytic leukemia 64
Acute promyelocytic leukemia presented as a relapse of acute myeloid leukemia 63
BENDAMUSTINE AND ALEMTUZUMAB (BEN CAM) COMBINATION IN RELAPSED AND REFRACTORY CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL): PRELIMINARY REPORT OF THE ITALIAN TRIAL 62
Treatment of chronic lymphocytic leukemia in the new drugs era: the state of art in the Italian landscape 62
Bleeding diathesis associated with acquired von Willebrand Syndrome in three patients with chronic lymphocytic leukemia 61
REGULATION OF HIF-1 alpha IN TP53 DISRUPTED CHRONIC LYMPHOCYTIC LEUKEMIA CELLS AND ITS POTENTIAL ROLE AS A THERAPEUTIC TARGET 56
Bleeding diathesis associated with acquired von Willebrand Syndrome in three patients with chronic lymphocytic leukemia 55
Immunotherapeutic strategies in chronic lymphocytic leukemia: advances and challenges 54
Monoclonal antibodies as selective diagnostic and therapeutical tools in benign and neoplastic prostatic pathologies 51
Response to the conjugate pneumococcal vaccine (PCV13) in patients with chronic lymphocytic leukemia (CLL) 51
Totale 10.322
Salva come PNG Salva come JPEG
Categoria #
all - tutte 39.870
article - articoli 0
book - libri 0
conference - conferenze 21.690
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 61.560
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020507 0 0 0 0 0 0 0 0 109 143 132 123
2020/20211.721 146 122 75 150 235 95 99 132 137 81 226 223
2021/20221.863 81 44 84 163 108 42 237 133 49 197 417 308
2022/20232.278 247 219 66 235 185 571 171 147 227 62 94 54
2023/2024968 114 183 61 43 50 171 23 71 7 55 64 126
2024/20252.010 16 108 123 314 745 205 212 216 71 0 0 0
Totale 11.974